







Research Ethics Manual

Research Ethics and Intellectual Property Committee



Table of content

Topic	Page
1. Introduction and background	2
2. What is ethics?	2
3. Scope of the guideline	2
4. The role of the ethics committee	2
5. Guidance on ethical approval for Research	3
6. Guiding ethical principles	3
7. Matters of ethical concern in research	4
8. Responsibilities of Research Supervisors and research students	8
9. Collaborations	8
10.Research Misconduct	8
11.References	10
12.Appendices	11

1. Introduction & Background

The birth of the concept 'research ethics' began with desire to protect the right of human subjects involved in research. The Universal Declaration on Bioethics and Human Rights that was developed by the UNESCO in 2005, includes the principles that should be respected in any research involving human participants.

MSA University encourages research in the pharmaceutical field, by offering well equipped research laboratories to researchers and undergraduate students. Researchers should be aware of the basic ethical principles and policies, which are made to ensure safety and dignity of participants, care of animals used in research and finally research integrity. Hence, the ethics committee in the faculty of pharmacy has prepared this ethics manual to serve as a guideline for researchers helping them in maintaining the integrity of their research.

2. What is ethics?

Ethics is a branch of philosophy that addresses questions about morality or the study of the disposition, character, or attitude of a specific person, group of people or culture, and ways of promoting or perfecting it. Bioethics is the morality of life sciences.

Ethics can also be considered as a moral principles system. They affect how people make decisions and lead their lives. Ethics, in this context, is concerned with what is good for individuals and society which is described by moral philosophy.

3. Scope of the guidelines

This guideline together with existing laws and regulations serve as the basis for the Research Ethics Committee (REC) to perform its function in ethical evaluation of proposed research. This manual is concerned only with ethical issues related to scientific research.

4. The structure and the role of the Research Ethics Committee (REC)

The Research Ethics committee (REC) of the Faculty of Pharmacy was established in November 2010. The Ethics committee ensures that the Faculty is following the ethical and safety measures in research. The REC is a member in the Egyptian Network of Research ethics committees (ENREC) and is registered in the US Office for human research protection (OHRP) as an active valid Institutional Review Board (IRB) with an IRB # 00010491. Additionally, the faculty has signed a collaboration protocol with Cairo University- Institutional Animal Care and Use Committee (CU-IACUC) to establish a framework for collaboration in the animal research ethics field so that the approval of any ethics proposal from MSA side is in turn accepted by Cairo University and vice versa.

The board of the REC includes faculty staff members from different specialties, and physician, in addition to a layman and a lawyer.

The aim of the REC in reviewing pharmaceutical based research is:

- Protecting the rights, safety, and well-being of research participants. The goals of research should not supersede the health of participants.
- Supporting and safeguarding the wellbeing of animals used for scientific research
- *Taking into consideration the principle of justice*. The benefits and burdens of research should be distributed fairly among all researchers.
- Evaluating the ethical acceptability of research before the enrollment of the participants in a study; accordingly examining financial and scientific aspects.

5. Guidance on ethical approval for Research

- All the faculty staff members must assure that their personal research or those that carried out under their supervision follow the ethical principles in this manual.
- Since MSA University is going green, therefore the ethics committee has shifted to the use of electronic ethics application form and the whole process of evaluation is done online.
- Each researcher should obtain the approval of the REC before beginning the practical steps. He/she must fill an application form online [Application form for graduation project research (appendix I) or Application form for postgraduate research (Appendix II)] and present it to the REC.
- The application form consists of three sections:
 - Section A (Obligatory): This section should be filled with information on the applicants, research aim, objectives, protocol of work and information about any collaborating institution.
 - o **Section B (optional)**: for researches involving human participants.
 - **Section C (optional):** This section should be filled for researches that involve working on animals.
- Researchers are not allowed to begin their research except after receiving written approval (annex V) on the research protocol from REC. The decision is taken within two weeks of receiving the ethics application form.
- After reviewing the proposed research, the REC will reach one of the following decisions:
 - 1. Approval.
 - 2. **Approved after modification** Researcher will not begin his/her work except after changing the protocol of work according to the specified conditions by the REC.
 - 3. **Disapproved** the researcher will not be allowed to begin this research due to reasons mentioned by the EC.

When the researcher decides to make any changes in the research protocol of previously approved research, he/she must fill a complementary ethics form (Appendix III) /Progress report (Appendix IV), describing these changes or research progress. The REC will then evaluate these changes ethically and reach one of the three previously mentioned decisions.

6. Guiding ethical principles

The following principles and values should be followed in all research carried out in MSA:

- **6.1 Integrity**: Researchers must always be honest.
- **6.2 Respect for persons:** Researchers must treat participants and research subjects with respect. Obtaining informed consent from participant is an important form of respecting persons.
- **6.3 Beneficence:** Researchers must make efforts to secure the well-being of participants.
- **6.4 Non-malfeasance:** Researchers should always think of maximizing possible benefits and minimizing possible harms. The health conditions of researchers (Pregnancy and allergy) should be taken into considerations.
 - **6.5 Justice/Fairness**: Researchers should not only consider the benefits of the individual or organization but rather they should consider the benefits for the wider community.

7. Matters of ethical concern in research

7.1 Respect for the law and governmental policies

Research execution should comply with the Constitution of the Arab Republic of Egypt and Egyptian laws.

7.2 Relevance & integrity

- Any fabrication of research results or negligence for true observations is considered serious forms of misconduct.
- If the researcher wants to make changes on an approved protocol, he/she must obtain the REC approval. Disregarding the committee approval in this stage may lead the REC to stop the research.
- Meticulous record-keeping is a permanent reference for the researcher that helps him/her to disprove any allegation or falsification of data.

7.3 Plagiarism

- Authors who plagiarized others data and ideas and claim that they are their own are committing theft of intellectual property. Plagiarism is research misconduct.
- Plagiarized data in research include results and discussion sections from other publications.
- Author should cite work of others including the work in which he is a co-author.
- Researcher should cite work of others even if it is unpublished.
- Utilization of privileged information such as manuscript received for peer review is a serious form of plagiarism and theft for intellectual property.
- The University offer subscription to turnitin® application which facilitate checking the originality of presented theses and manuscripts.

7.4 Investigator Competence

Only qualified and competent investigators are allowed to conduct research. The following attributes should be found in researchers to be suitable for conducting research:

- Technical and research competence;
- Knowledge and experience in the required field;
- Ability to identify ethical issues.
- Can face ethically challenging situations in a responsible and appropriate way.
- Honesty and Integrity.

7.5 Ownership of and Access to Data

- Research data obtained in studies performed at MSA University belongs to it.
- Any member of the research group has the right to access data collected in the research.
- A principal investigator who leaves the University could make a copy of data to be able to continue the research in other institutes.
- Researchers who left MSA could access the data which they helped in obtaining.
- Each researcher in a group project should have a written agreement with the principal investigator, about the parts of the project he or she might continue to explore after leaving the group.
- Unique divisible materials prepared in the course of the research, such as, but not limited to; intermediates in a chemical synthesis, cell lines and reagents ... etc.

should be divided amongst the members of the research group. An agreement between researchers in group research should be made for non-divisible items.

- A written agreement should be made within group research to specify the rights of each researcher if a patent emerges from their work.
- An Invention Disclosure with the Technology Innovation Support Center should be made by researcher who has made a patentable finding.

7.6 Care and protection of researcher, research assistants, and environment

The safety of researchers must be ensured by adequate safety measures. Training on safety procedures must be done for all staff. Researchers must be aware of the possible health hazards (such as but not limited to, chemical, biological, physical.... etc.) in his/her research and the possible means of protection (Risk assessment).

Risk assessment refers to the description of the overall process or method for:

- Identifying hazards and risk factors that have the potential to cause harm (hazard identification).
- Analyzing and evaluating the risk associated with that hazard (risk analysis, and risk evaluation).
- Determining appropriate ways to eliminate the hazard, or control the risk when the hazard cannot be eliminated (risk control).

7.7 Matters of Ethical concern in researches involving human

7.7.1 Informed Consent

Human related researches that require ethical assessment and approval include:

- Invasive physical procedure, such as but not limited to the taking of blood samples
- Non-invasive procedures, such as but not limited to interviews, questionnaires, surveys, observation
- Accessing personal data and /or tissue

Researchers must obtain informed consent from the research participant before beginning research (Patient consent form). The consent form should be written in nativelanguage that the participant can understand. This requirement is important to respect human dignity and integrity.

- Consent should be made in both written and verbal form.
- When the participant is illiterate, a literate witness must confirm that the researcher has informed the participants of all relevant information.
- In the case of children participants, Informed consent should be obtained from their parents.

The four main requirements for informed consent are:

- 1. Disclosure:
- 2. Understanding or appreciation;
- 3. Voluntariness; and
- 4. Capacity to consent.

1. Disclosure

Disclosure refers to informing prospective participants by the nature of research to be done in detail and by appropriate language using patient information sheet.

To obtain informed consent, the following information must be disclosed to participants such as:

- a. That their participation in research is voluntary;
- b. The aim of the research
- c. The expected time period of his/her participation in the research;
- d. The nature of the experiments to which he/she will be subjected;
- e. What will be his/her responsibilities upon participation in research?
- f. The possible risks and hazardous that he/she may encounter from his/her participation in this research;
- g. The benefits that he/she might gain during participation in the research;
- h. What will happen in case of participant's injury during participation in research i.e Whether a compensation will be given to participant or not;
- i. Participant have the right to be informed of new findings in the research;
- j. The participant has the right to withdraw at any stage of the project:
- k. The extent of maintaining their confidentiality;
- 1. The contact details of researchers. Researcher must inform participants with their contact detail, in case the participant require additional information or suffer anadverse event;
- m. The qualifications of the researchers which make him/her suitable to conduct the research:
- n. Participants should know that they have the right to decide the future use of specimens obtained from them.

2. Understanding or appreciation

Age, maturity, intelligence, education, and belief system must be considered in the method used to obtain informed consent. The researcher must have the confidence that **te** participant understands and knows all the risks and benefits associated with the research. All participants' questions must be answered honestly.

3. Voluntariness

Researchers should obtain consent honestly. The consent will be invalid if given to researcher under compulsion.

4. Capacity to consent

Accepted consent is the one given by participant who is legally and factually capable to consent.

7.7.2 Confidentiality

Personal data is data relating to living individuals. It includes, but not limited to: Names, contact details of participants, answers to questionnaires, photographs, video, etc and Human biological material, e.g. blood, tissue.

The investigator must preserve the confidentiality of participants' personal data by making access to this data limited as possible and removing information that might lead to identification of participants, anonymizing data or by other means. Researcher should sign a declaration for preserving confidentiality of participants. This part of the declaration included in the ethics application form.

To ensure the security and confidentiality of the data collected, researchers should:

- Keep this data in a secure place such as locked cabinet or password-protected files
- Not share the data with persons outside the research group.
- Transfer the data in a secure manner.
- Keep the data till end of research and then dispose it securely.
- Anonymize data once collected and ensure that data is published only in its anonymized form.
- Personal data of participants should not be used in another purpose other than research.

7.8 Matters of ethical concern in animal research.

Researchers should only use animals in research when necessary and when they find that the expected knowledge obtained from the study is in the favor of harm/benefit balance. The use of animals in research, in MSA University, is regulated using the concept of 3R principles [Replacement-Reduction-Refinement] (Russel and Burch, 1959) as well as the following guidelines:

- Respect for life. All animals have to be treated in a way to maintain their dignity, basic needs of welfare life and species characterization.
- The researcher should provide the evidence of the absence of any alternative to animal experimentation (e.g. well established in-vitro method) before starting the experiment.
- Researchers are obliged to provide the animals with an appropriate environment which meets their physiological and behavioral needs including freedom of movement and appropriate social contacts and interactions.
- The animals should be kept in such a way that their physical functions and behaviors are not affected.
- The animals should be provided with suitable shelter, facilities and comfortable resting areas; ensuring that it is not exposed to adverse temperatures, weather conditions, or lack of oxygen.
- The number of animals, used in each research, should be kept to minimum, and the number of animals have to be calculated using a proper program for sample size calculation
- Reducing pain and suffering for animals should be ensured by best possible treatment. Therefore, the use of anesthesia and analgesia is **obligatory** when invasive procedures are used.
- The appropriate termination criteria and proper disposal of animals must beclearly stated in the ethics application. The method used for euthanization should not be painful or cause animal distress

 All researchers who handles the animals should be well-trained and should have the moral and scientific responsibility for planning and justification of proper animal experimentation.

8. Responsibilities of Research Supervisors and Junior Researchers

Both research supervisors and junior researchers have ethical responsibilities.

- The researcher should be well trained on the necessary skills and knowledge required for working as research investigator.
- The primary supervisor should provide suitable research environment for the researcher to acquire both the conceptual and technical skills of the field.
- The supervisor should provide the researchers a high quality training experience. It is the responsibility of the mentor to guide the research students during their work and interact personally with researcher on a regular basis to give timely feedback regarding research findings and progress.
- The number of researchers in lab should be limited to the number that allows the supervisors to train them appropriately.
- Junior researchers have responsibilities to their supervisors and to the institution as well. They must adhere to this ethical guideline for researches, as well as safety guidelines.

9. Collaborations

Collaborative research includes researches between researchers with distinct capabilities working together on a specific research.

- MSA University encourages research collaboration within the university as well as with other institutions.
- Rules for collaborations should be discussed among all participants from the beginning.
- Written agreements should be made whenever the collaborations involve exchange of biological materials.
- Written agreements should be made for any collaboration between laboratories in MSA and research group in another universities, institutions and/or research centers. This agreement provides a protected environment for long-term collaborations and protects the intellectual property rights to MSA inventions. These agreements are handled by the Technology Innovation Support Center of the university.
- In case of making practical work in a collaborating institution, the research should comply with the research ethics guidelines of that institution and external approval should be presented to the REC.

10. Research Misconduct

The administration of MSA University deals with allegations of scientific misconduct seriously. The procedures followed by the administration of MSA University are intended to process allegations of scientific misconduct promptly, confidentially, and fairly.

• Recording, analyzing and presenting data should be done with honesty and integrity.

outlying data points is research misconduct.	

References

The following documents have been taken into consideration and/or referred to for the policy review.

- 1. BBSRC Statement on safeguarding good scientific practice, revised (2013).
- Canadian Center for Occupational Health and Safety. https://www.ccohs.ca/oshanswers/hsprograms/risk_assessment.html(access">https://www.ccohs.ca/oshanswers/hsprograms/risk_assessment.html(access">https://www.ccohs.ca/oshanswers/hsprograms/risk_assessment.html(access">https://www.ccohs.ca/oshanswers/hsprograms/risk_assessment.html(access">https://www.ccohs.ca/oshanswers/hsprograms/risk_assessment.html(access") date 10/8/2020)
- 3. Ethics Education Programme (Bioethics Core Curriculum) Sector for Social and Human Sciences UNESCO.
- 4. Ezekiel J. Emanuel et al., (2011). The oxford textbook of clinical research ethics. Oxford University press.
- 5. Elliott C. Kulakowski and Lynne U. Chronister (2006). Research Administration and Management. Jones and Barlett international.
- 6. IACUC Guidelines for the Humane Euthanasia of Laboratory Animals (2013). University of Texas.Office of research support in the university of texas guideline
- 7. MRC Ethics Guide: Medical research involving children. Medical Research Council, (2004).
- 8. National Research Council: Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington D.C., (2011), ISBN 978-0-309-15401-7
- 9. Russell, W.M.S. and Burch, R.L., (1959). The Principles of Humane Experimental Technique, Methuen, London. ISBN 0900767782
- 10. UNESCO: Universal declaration on bioethics and human rights (2005) Office of International Standards and Legal Affairs. http://portal.unesco.org/en/ev.phpURL_ID=31058&URL_DO=DO_TOPIC&URL_SECTION=201.html (access date:10/8/2020)
- 11. UK Research Integrity Office (UKRIO) Code of Practice for Research, (2009).
- 12. http://worldanimal.net/our-programs/model-law-project/part-2-proposal-for-the-wording-of-a-new-animal-welfare-act/chapter-3-keeping-of-animals-care-of-animals. (access date 10/8/2020)

Appendices

Graduation Project Ethics Application Form

OFFICE USE ONLY			
Date submitted:		Ref:	
Reviewers:		Decision:	

Research Ethics Committee-Faculty of Pharmacy Application Form

Note for the applicant

The MSA Faculty of Pharmacy Research Ethics Committee (REC) is responsible for ensuring that any research undertaken by faculty members or students, or by other institutions when in collaboration with the University, meets recognized ethical standards. Where ethical issues exist in a research proposal the research should not commence until approval has been obtained from the REC.

The Application Form consists of 3 sections and 4 Annexes:

····· · · · · · · · · · · · · · · · ·		
TABLE OF CONTENTS	MANDATORY / OPTIONAL	Used Sections & Annex are marked with √
SECTION A: General Information, study description, research procedures General information, study description, research procedures and Supervisor Declaration	MANDATORY	
SECTION B: Researches involving human participants	Optional	
SECTION C: Researches involving animal use	Optional	
Annex I Patient consent form	Optional	
Annex II Participant Information sheet	Optional	
Annex III Medicinal products/Cosmetics/Fo od supplement and Medical devices	Optional	
Annex IV Risk Assessment form	MANDATORY	

This Application Form is divided into Sections.

Section A is Mandatory. Sections B and C are optional.

For any inquiries, please consult the Head of the ethics committee, Dr.Reham Wasfi (Room G009) or the committee members.

General rules applying to research projects carried by graduating students in the faculty of Pharmacy

- a) The authorship for any articles based on results of this research must be according to the International Committee of Medical Journal Editors (ICMJE) which stated that authorship should be for contributors who share in all the following points
- i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- ii) Drafting the work or revising it critically for important intellectual content; AND
- iii) Final approval of the version to be published; AND
- iv) Able to defend the article and responsible for accuracy of work
- b) If the applicant have made any changes in his/her project that differs from that in the first submitted ethics application form, he/she must submit a complementary form with that changes and he should obtain another approval from the committee.

			COMMENTS
	OF	FFICE USE ONLY	
Date submitted:		Ref:	
Reviewers:		Decision:	
Res		committee-Faculty of Pharmacy oplication Form	
		Section A	
Title of the Research	Study:		
Project code:			
Part I: Applicant an	d Supervisor Detai	ils	
1. Name of Applicant	ts (students)		
ID of MSA students (if applicable)		
2. Status (Undergrad	luate, MA or MSc)		
3. E-mail Address			
4.Telephone Number	Г		
6. Department			
7. Supervisor's name	3		
8. Supervisor's affilia	ation		
9. Supervisor's E-ma	nil address		
Section II:Summary			
9. Brief outline of the	proposed project (i	nclude project design and methodology).	
10 List the study aim	ns objectives and be	enefits of this proposed research.	
10. List the study am	is, objectives and be	enents of this proposed research.	
11. What do you consand what steps will b		ethical issues which may arise with the proposed study these?	

	OF	FICE USE ONLY					
Date submitted:		Ref:					
Reviewers:		Decision:					
Res	Research Ethics Committee-Faculty of Pharmacy Application Form						
40. Have any sallaha	•	•					
resources will be ne			stitutions or departme icipate?	ents whose			
	ain ethical issues in	that work? (Describ	tions or departments. be the steps taken to a form)				
Applicant's							
Signature							
Supervisor's Signature		Date					
Head of the Research Ethics Committee		Date					
	Super	visors Declara	tion				
For the project unde		VIGO O DOO GI GI					
Carried by:	i dio ddo.						
Supervisor Name:							
•	r this project I have	w doclare that I am	awaro of my obligation	on to respect all			
			aware of my obligation ensure that the stud				
all the work according			onouro mar mo orau	onto navo dono			
In particular, I will							
		ın, except after info	rming the ethics com	mittee via a			
written form and acq		of any information b	prought to my attention	on during the			
performance of this		or any information t	orought to my attention	auring the			
		a facility outside MS	SA will follow all ethic	al and safety			
rules and all experim	ents carried by this	facility will be ment	tioned in the ethics fo	orm.			
- Not make any infori	mation available to t	he public, even afte	r completion of my as	signment.			
Supervisor Signature	9 :			Date			
-							

Section B

a. HUMAN PARTICIPANTS - SELECTION AND RECRUITMENT

Please describe:

M	М		-
111	/ \7	ЛΕ	

	OF	FICE USE ONLY	
Date submitted:		Ref:	
Reviewers:		Decision:	
Res	search Ethics C	committee-Facu	ulty of Pharmacy
	Ap	plication Form	ı
1. How many particip involved?	ants are to be		
2. What are the main exclusion criteria for participants?			
3. Will any participar research study be si involved in any other	multaneously		
4. Will human particip			
compensation for pa			
L IIIIMANI DADTICID	ANTO INFORMER	CONCENT	
b. HUMAN PARTICIP This part for the case		CONSENI	
1. Will informed cons			
If no, please justify	ent be obtained: ,		
2. How will informed			
obtained and by who			
right to refuse to par			
right to withdraw fro study? Please elabor			
4. Will there be a time			
giving information as consent?			
5. Will any research punder the age of 18?			
c. Data Protection an	d Confidentiality		
		sions of the Data	Protection Act and the University
		a Protection Policy	
1. Will the research in potential research page			any stage (including identification of
potential research pa			outside the research facility, or within
	the facility by those v		
	Electronic transfer by	magnetic or optical r	media, e-mail or computer networks
	Sharing of data with	other organizations	
	Export of data outsid	•	
Use of personal addresses, postcodes, faxes, e-mails or telephone numbers			•
Publication of direct quotations from respondents			
		at might allow identifi	cation of individuals
	Use of audio/visual re		
	Storage of personal of	data on any of the foll I	
			Manual files MSA computers
			MSA computers Home or other personal computers
			Laptop computers
			tiality of personal data? Give details res have been used and at what

00	v		М.	0
	M١	ИΕ	N	15

	OF	FICE USE ONLY		
Date submitted:		Ref:		
Reviewers:		Decision:		
Res		ommittee-Facu plication Form	ulty of Pharmacy	
3. Where will the anal undertaken?	ysis of the data fron	n the study take pla	ce and by whom will	it be
4. Who will have cont	rol of and act as the	custodian for the d	lata generated by the	study?
			1	
Applicant's Signature				
Supervisor's Signature		Date		
Head of the Research Ethics Committee		Date		
		Section C		
This part is for the stu	udies that involves l			
I. What is the purp	ose of using anin	nal in this study?	?	
1.Field study/capture				
2.Behaviour observat		g (g ,		
3.Harvesting of tissue	es from dead animal	s		
4.Dissection of dead				
5.Surgical procedures	s			
6. Administration of p	harmaceutical agen	its		
7.Infection with micro	bial agents and/or p	parasites/ testing of	toxins [i]	
8.Production of antise	era			
9.Feeding studies, inc	cluding diet modifica	ation		
10.Animals with alteroccurring mutation)	ed genetic make-up(manipulated, modif	ied, naturally	
11. Other Procedures	: if selected, please	write details in the	box below	
II Calculation of a	nimal cample oi-	•		
II. Calculation of a				
1. How many animal of the commended me	-			

00			1	T C
	M	М		4 I 2

	OF	OFFICE USE ONLY			
Date submitted:		Ref:			
Reviewers:		Decision:			
Res		ommittee-Facu pplication Form	Ilty of Pharmacy		
3. Provide your calcu	ulation details here				
	e of numbers used in out link for this study		Hypothesis or a previous study and		
III. Animal Housin	ng				
a) Housing					
Explain where animal maximum/minimum a bedding, hiding areas	s will be housed and t nimals per cage/pen, i	the type of housing. Fisolation, group housi hment, conditioning p	cant impact on animal well-being. coints to consider are the ng (stocking rates, sexes), shelter, eriod, day to day husbandry of the nals is approximated.		
b) Site where proced	dures are to be carrie	d out			
c) Holding time					
What is the maximum time for which any individual animal will be held?					
d) Monitoring by Inv	estigators				
the method and frequ problem is identified?	ency of monitoring ani Please include the cri	imals during and afte iteria used for interve	oughout the project including: Details of r procedures. What will be done if a ntion, treatment, or withdrawal of the ement of veterinary and other		
e) Fate of Animals					
What will happen to a How will this be don			t? If animals are to be euthanized,		

ENTS

OFFICE USE ONLY				
Date submitted:		Ref:		
Reviewers:		Decision:		

Research Ethics Committee-Faculty of Pharmacy Application Form

- After the end of the experiment the animals will be anesthetized, the animals will be euthanized by cervical dislocation and that will be done in the presence of supervisor. The blood and liver samples will be collected and stored till time of analysis.
- The dead animals will be delivered to the sanitation companies and disposed according to the official biological waste disposal system.

f) Risks

Please specify any special risks to other animals or humans arising from the project

- •Risk of rat bite.
- •Risk of syringe injury.
- •Blood contamination risk.
- Injury of rat

Applicant's Signature	Date
Supervisor's Signature	Date
*Signature of the Head of pharmacology department in MSA	Date
Head of the Research Ethics Committee	Date

*This signature is required only If this part of practical work will be done in the Animal House of MSA

Annex I

Patient Consent Form

Title of Research:

- I confirm that I have read and understand the Information Sheet for the above study, have had the opportunity to ask questions, and understand what I am expected to do as a volunteer.
- I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my rights being affected.
- I would like/not like my own results reported back to me, understanding that no interpretation may be possible.
- I do/do not agree that photographs and video material recorded during the study may be used for illustration purposes in reports and any subsequent journal articles. This is on the understanding that, while every effort will be made to preserve my anonymity, this cannot be guaranteed.
- I do/do not agree that samples provided during the study may be stored beyond the study duration for further research. I understand that these samples will be made anonymous and not traceable back to me.

أؤكد أنني قد قرأت وفهمت ورقة معلومات عن الدراسة المشار إليها أعلاه، فقد أتيحت لى الفرصة لطرح الأسئلة ، وفهمت ما يتوقع مني أن افعله كمتطوع.أنا أفهم أن مشاركتي هي طوعية وأنني حر في الانسحاب في أي وقت ، دون إبداء أي سبب، من دون أن نتأثر حقوقي. - أود / لا أود أن اعرف نتائج . - اوافق / لا أوافق على أن يمكن استخدام الصور ومواد الفيديو التي سجلت خلال دراسة لأغراض التوضيح في التقارير والمقالات الصحفية. هذا على أساس أنه، في حين استخدامها سيتم بذل كل جهد ممكن للحفاظ على عدم استخدامها سيتم بذل كل جهد ممكن للحفاظ على عدم تخزين العينات المقدمة أثناء الدراسة نتجاوز مدة الدراسة لاجراء مزيد من البحوث.

Participant signature:	توقيع المشارك:
------------------------	----------------

Consent form for children and illiterate

I have read the foregoing information, or it has been read to me. I have had the opportunity to ask questions about it and any questions that I have asked have been answered to my satisfaction. I consent voluntarily for (child) to participate as a participant in this study and understand that I have the right to withdraw her/him from the study at any time without in any way affecting our care at this Centre.

Print Name of Parent or Guardian	Date
Signature of Parent of Guardian	Date

lf illiterate

A literate witness must sign (if possible, this person should be selected by the participant and should have no connection to the research team). Participants who are illiterate should include their thumb print as well.

I have witnessed the accurate reading of the consent form to the potential participant, and the individual has had the opportunity to ask questions. I confirm that the individual has given consent freely.

Print name of witness	Date
Signature of witness	Date



Research Ethics Committee-Faculty of Pharmacy

Annex I

Patient Consent Form

I have accurately read or witnessed the accurate reading of the consent form to the Parent/guardian of the potential participant and the individual has had the opportunity to ask questions. I confirm that the individual has given consent freely.

Print name of researcher	Date
Signature of researcher	Date

A copy of this Informed Consent Form has been provided to the parent or guardian of the participant _ (initialed by researcher/assistant)

	OFFICE USE ONLY					
Date submitted:		Ref:				
Reviewers:		Decision:				
		Annex II				
	Participa	ant Information	Sheet			
Invitation: You are	invited to participate					
Conducted by (plea	ase include the name	es of the students a	nd their ID numbers):			
Cupanicad by (pla	anningly do the group		iliation).			
Supervised by (pie	ase include the supe	ervisor name and am	mation):			
University. Before	you decide whether	or not to participate	of the Faculty of Pharmacy-MSA in this study, please make sure that			
would your particing you sign the partic	you are fully aware with the details of the study and what exactly is required from you and how would your participation affect the study. Please take the time to read the following parts before you sign the participant consent form. Your participation in this research is voluntarily and you are free to withdraw at any time, without providing reasons.					
What is the purpose of this research? Write a brief outline on this study.						
What is required from the participant? And why is he/she been invited?						
what is required in	om the participant?	And why is he/she b	een mvitea ?			
What are the risks associated with the proposed procedure(s)?						
What is the expect	What is the expected time for finishing the research?					
I declare that I have	ve read all the infor	mation in the parti	icipant information sheet and			
	ate in this research					
Participant signatu	ire:					
If you find any prob	If you find any problem in this research you can contact the following researcher					
Name:						
Contact informatio						
	re that he/she is re d participant's per		erving the confidentiality of			
Researcher (studer	nts) signature:					
i e e e e e e e e e e e e e e e e e e e						

ملحق || ورقة معلومات للمشاركين في البحث

				COMMENTS
	OFFICE USE O	NLY	1	
Date submitted:	Ref:			
Reviewers:	Decision:			
	Annex II Participant Informa	tion		
	شوان:	ثية بع	رسالة دعوة: أنت مدعو للمشاركة في دراسة بد	
			اسماء الباحثين:	
يرجى أخذ الوقت الكافي		م لماذا	هذا البحث تم الموافقة عليه من قبل لجنة الأ في هذه الدراسة، فمن المهم بالنسبة لك أن نفه لقراءة ما يلي قبل التوقيع على استمارة موافقة أى وقت، دون إبداء أسباب	
		البحث	ماهى اهداف هذا البحث؟ اكتب باختصار خطوات	
	•	•		
	074.5.44	400		
	م للمشاركة؟	عونكم	ما هو الدور المطلوب من المشارك؟ و لماذا تم د	
			ما هي المخاطر المرتبطة بهذا الإجراء؟	
			الوقت المتوقع لانتهاء البحث	
			, , , , , ,	
	ر. و ورقة المعلومات مشارك وافقت على المشاركة ا	12.		
ئي هدا البخت	ي ورقة المعلومات مسارك والعلق على المساركة	رده شي	افر جانسي قد فرات جميع المعقومات الوا توقيع المشارك:	
			وقيع المسارق	
	to the beautiful to the state of the state o	* ***		
	ي هذا البحث يمكنك الاتصال بالباحث.	ىكلە ق		
			الأسم:	
			معلومات الإتصال:	
ئىاركىن.	رية المعلومات المجمعة و البيانات الشخصية للما	علی سر	يقر الباحث بمسؤليته على الحفاظ	
			توقيع الباحث:	
			توقيع البحث.	

COMMENT	SO	М	M		V	K
---------	----	---	---	--	---	---

OFFICE USE ONLY				
Date submitted:		Ref:		
Reviewers:		Decision:		

Annex III

Annex III Medicinal products/Cosmetics/Food supplement and Medical devices

This annex needs only to be completed if relevant to research. It should be completed when Drug or medicinal products or medical devices are used on Human participants or animals.

Title of Research:

- 1. Is the study initiated /sponsored by pharmaceutical or other industrial company?
- 2. Does the study involve:
 - Pre-marketing use of a product?
 - A new use for marketed product?
 - Studying the effect of marketed product?

1) Drug and Medicinal product

A medicinal product is: (a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or

(b) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

a) Details of the medicinal product:								
Approved Name								
b) Dosage regimen used:								
Dosage & Frequency Route								
c) Is this dosage regimen								
- The recommended dose regimen by the manufacture								
- New dose regimen								

- d) What are the possible side effects?
- e) What is the pharmacological action of this drug?
- f) What are the arrangements for dispensing medicinal product? (please give details)

2) Medical devices

- Is the focus of this study/trial to investigate/evaluate a medical device?
- If yes, what is the name of the medical device or device nomenclature (system of naming the medical device)?
- · If yes, please provide a general description of the medical device and the medical use in patients.
- If an application to conduct a clinical investigation of a medical device

COMMENTS

	(OFFICE USE ONL	_Y
Date submitted:		Ref:	
Reviewers:		Decision:	

(a) Does the device have a CE mark?	
• If the device has a CE mark, is it proposed to use the device within the terms of its CE mark or outside the terms of its CE mark?	
If outside, please elaborate:	
CE mark* number:	
What are the possible hazards and adverse effects?	
Who will fit or apply the device for participant?	

NOTE: CE Marking on a product is a manufacturer's declaration that the product complies with the essential requirements of the relevant European health, safety and environmental protection legislation, in practice by many of the so-called Product Directives.

	SIGN HERE TO A	DDDOVE TU	E FILLED CONTENT IN ANNEX IV			OFFIC	E USE ONLY				
			THEED CONTENT IN ANNEX IVE	Date Reviewers:		Rof.					
	Supervisor signature Hazards inherent in the task or	e:		Reviewers:		Decision:					
Equiment / Tool / Biological agent /Waste	process include all the significant hazards that are expected or are foreseeable in the context of the work or	Person (s) at risk	Precautions (control measures) include precautions for all individuals (groups that may be affected by the hazards you have identified e.g. staff, students, passersby	Curr	ent Risk Rating		Further control measures required and by whom	Final	Current Risk Ratin	g	Remark s
	process that is being undertaken and where it will be done			Likelihood	Severity	Risk rating	(Only required for "Medium" and "High" risk ratings)	Likelihood	Severity	Risk rating	
Equipment	and physical hazards E.	g.: tools, ma	chinery, work at height, electric	ity, high pr	essure, high	temperatu	ıre , UV , laser Only significant l	hazards ne	ed to be reco	orded.	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
e.g: physic	cal or verbal attack , o	disability o	r health problem, getting los	st or strar	ided by trai	(U)	ultural or legal differences			(0)	
						(0)				(0)	
Any micro- allergy, toxi	icity and other hazards o	of human hea	doparasite including any which alth This includes bacteria ,viru ood borne infection, skin conta	ses ,fungi			nay cause infection ,			(U)	
						(0)				(U)	
						(0)				(0)	
						(0)				(0)	
Environmenta	al impact										
	n and waste, deposition of ru	bbish									
						(0)				(0)	
						(0)				(0)	
Other hazards	5					(U)				(0)	
						(-,				(-)	

			PROVE THE		OFF	ICE USE O	NLY				
		ANNEX	CONTENT IN	Date submitted:		Ref:					
	Supervisor signature:			Reviewers:		Decision:					
	Supervisor signature:										
	Reviewer signature:										
			hazards e.g.: Toxic by inhalation by inhalation"	on, irritant ,corrosive	, flammable	e, explosive Includ	le routes of exposu	re: skin ser	nsitization,		
Chem ical Comp ound s	Hazards inherent in the chemical Including all the significant hazards that are expected or are foreseeable in the context of the work or process that is being undertaken and where it will be done	Person (s) at risk	Precautions (control measures) include precautions for all individuals /groups that may be affected by the hazards you have identified e.g. staff, students, passersby	Currer	nt Risk R	ating	Further control measures required and by whom	Fina	l Current Rating	Risk	Co mea in ca acci I sp
				Likelihood	Severit y	Risk rating	(Only required for "Medium" and "High" risk ratings)		Severit y	Risk rating	

		TO APPROVE THE FILLED CONTENT IN ANNEX IVI		OFFICE USE ONLY							
		ANNEATO		Date submitted:		Ref:					
	Supervisor signature:			Reviewers:		Decision:					
	Supervisor signature:										
	Reviewer signature:										
		Annex IVb - Risl	k Assessment Form								
		"Chemical haza routes of exposu	rds e.g.: Toxic by inhalation, i ure: skin sensitization, sensitiz	rritant ,corrosive, flam cation by inhalation	nmable, explo	osive Include					
Chemical	Hazards inherent in the chemical Including all the significant hazards that are expected or	Person(s) at	Precautions (control measures) include precautions for all individuals /groups that	Curr	Current Risk Rating		Control measures in case of accidental spillage	Storage	Disposal	Link to relevant MSDS	Remarks
Compounds	are foreseeable in the context of the work or process that is being undertaken and where it will be done	risk	may be affected by the hazards you have identified e.g. staff, students, passersby	Likelihood	Severity	Risk rating					
						0					
						0					
						0					
						0					
						0					
						0					
						0					
						0					
						0					

Risk Matrix

Risk rating is calculated by multiplying value of likelihood and severity/impact

A value should be assigned for the likelihood of an incident occurring based on the hazard from 1 to 5 and a value for theseverity / impact of the hazard from 1 to 5. e.g. $3 \times 2 = 6$ (low hazard).

	5 CATASTROPHIC	5	10	15	20	25		
	4 MAJOR	4	8	12	16	20		
SEVERITY /	3 SERIOUS	3	6	9	12	15		
IMPACT	2 MODERATE	2	4	6	8	10		
	1 MINOR	1	2	3	4	5		
		1	2	3	4	5		
		RARE	UNLIKELY	POSSIBLE	LIKELY	ALMOST CERTAIN		
	_	LIKELIHOOD						

Risk score = likelihood of the hazard to cause harm impact							
Medium	·						
Rating 8 - 12	Rating 1 – 6						
Urgent review of the equipment, activities, system of work within the workplace with the aim of lowering the risk to the next level.	Usually, no further actionwill be required except formonitoring to ensure the risk does not change. However, if it is possible to reduce the risk levels still further, by using controls that are "reasonably practicable".then this						
	Medium Rating 8 - 12 Urgent review of the equipment, activities, system of work within the workplace with the aim of lowering the						

		REVIEWE	R CHECK	LIST				
		OFFIC	E USE ONLY					
	Date submitted:		Ref:					
	Reviewers:		Final Decision:					
		Ethics Committee-Fa		Application Form				
	The Application Form consists of		exes:					
	TABLE OF CONTENTS	Used Sections & Annex are marked with √	Decision	Supervisor Signature	Student(s) Signature	Reviewer Signature	Head of Ethics Committee Signature	Head of Pharmacology Department Signature
М	SECTION A: General Information, study description, research procedures General information, study description, research procedures			Not signed	Not signed		Not signed	
M	SUPERVISOR DECLARATION			Not signed		Not signed		
	SECTION B: Researches involving human participants			Not signed	Not signed]	Not signed	
	SECTION C: Researches involving animal use			Not signed	Not signed]	Not signed	Not signed
	Annex I Patient consent form							
	Annex II Participant Information sheet					Not Checked		
	Annex III Medicinal products/Cosmetics/Food supplement and Medical devices					Not Checked		
М	Annex IVa Risk Assessment form			Not signed				
М	Annex IVb Risk Assessment form			Not signed				

Graduation Project Complementary Ethics Application Form

		OFFICE USE ONL'	Υ	COMMENTS
Date submitted:		Ref:		
Reviewers:		Decision:		
	Research Ethic	s Committee-Fac	ulty of Pharmacy	
	Complemen	tary Form for Res	search project	
Proje	ect title			
	ct code			
Depa	rtment			
Applican	nt Name(s)			
Applica	ant ID(s)			
-	ervisor			
ethics committee: (1)) in the beginning of se	econd part of research p	heir project. This form must be delivered to the roject (for all projects) and (2) in case of any nics application form in part one.	
of work	cations in protocol			
Other modification				
Is there any docum going to attach to				
Write the modifi	cations that you a	re going to make in	your project.	
			1	
Applicant's Signature		Date		
Supervisor's Signature		Date		
	This part is	filled by the Ethi		
Is this modificat	ion considered?			
The ethics comr	nittee comment ai	nd recommendation	ns on these modifications	

USE ONLY	COMMENTS
ate	

				COMMENTS			
	OFFIC	E USE ONLY					
Date submitted:	Ref:						
Reviewers:	Deci	cision:					
Fill this part	in case of changing	g the number	er of animals from those				
		ted in part or					
	A	Annex I					
Attited 1							
II. Calculation of a	nimal sample size						
1. How many animal	groups will be included?	?					
2. Recommended me	thods for calculation of s	sample size:					
3. Provide your calcu	lation details here						
		r calculations?	Hypothesis or a previous study a	nd			
if a previous study p	ut link for this study						

	SIGN HERE TO A	DDDOVE TU	E FILLED CONTENT IN ANNEX IV			OFFIC	E USE ONLY				
			THEED CONTENT IN ANNEX IVE	Date Reviewers:		Rof.					
	Supervisor signature Hazards inherent in the task or	e:		Reviewers:		Decision:					
Equiment / Tool / Biological agent /Waste	process include all the significant hazards that are expected or are foreseeable in the context of the work or	Person (s) at risk	Precautions (control measures) include precautions for all individuals (groups that may be affected by the hazards you have identified e.g. staff, students, passersby	Curr	ent Risk Rating		Further control measures required and by whom	Final	Current Risk Ratin	g	Remark s
	process that is being undertaken and where it will be done			Likelihood	Severity	Risk rating	(Only required for "Medium" and "High" risk ratings)	Likelihood	Severity	Risk rating	
Equipment	and physical hazards E.	g.: tools, ma	chinery, work at height, electric	ity, high pr	essure, high	temperatu	ıre , UV , laser Only significant l	hazards ne	ed to be reco	orded.	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
						(0)				(0)	
e.g: physic	cal or verbal attack , o	disability o	r health problem, getting los	st or strar	ided by trai	(U)	ultural or legal differences			(0)	
						(0)				(0)	
Any micro- allergy, toxi	icity and other hazards o	of human hea	doparasite including any which alth This includes bacteria ,viru ood borne infection, skin conta	ses ,fungi			nay cause infection ,			(U)	
						(0)				(U)	
						(0)				(0)	
						(0)				(0)	
Environmenta	al impact										
	n and waste, deposition of ru	bbish									
						(0)				(0)	
						(0)				(0)	
Other hazards	5					(U)				(0)	
						(-,				(-)	

		TO APPROVE THE FILLED CONTENT IN			OFFICE USE ONLY						
		ANNEX		Date submitted:		Ref:					
	Supervisor signature:			Reviewers:		Decision:					
	Supervisor signature:										
	Reviewer signature:										
			hazards e.g.: Toxic by inhalation by inhalation"	on, irritant ,corrosive	, flammable	e, explosive Includ	e routes of exposu	re: skin ser	nsitization,		
Chem ical Comp ound s	that are expected or are foreseeable in the context of	Person (s) at risk	Precautions (control measures) include precautions for all individuals /groups that may be affected by the hazards you have identified e.g. staff, students, passersby	Currei	nt Risk R	ating	Further control measures required and by whom	Fina	Current Rating	Risk	(m in ac
				I Stroliko o d	Severit	Diale matics or	(Only required for "Medium"		Severit	Risk	

Likelihood

Risk rating

		TO APPROVE THE FILLED CONTENT IN ANNEX IVb		OFFICE USE ONLY							
		ANNEA IVD		Date submitted:		Ref:					
	Supervisor signature:			Reviewers:		Decision:					
	Supervisor signature:										
	Reviewer signature:										
		Annex IVb - Risl	Assessment Form								
"Chemical hazards e.g.: Toxic by inhalation, routes of exposure: skin sensitization, sensi				rritant ,corrosive, flam zation by inhalation	mable, explo	osive Include					
Chemical a	Hazards inherent in the chemical Including all the significant hazards that are expected or	cal Precauti Il the measur azards precau cted or Person(s) at individual		Precautions (control measures) include Curro precautions for all individuals /groups that			Control measures in case of accidental spillage	Storage	Disposal	Link to relevant MSDS	Remarks
	are foreseeable in the context of the work or process that is being undertaken and where it will be done	risk	may be affected by the hazards you have identified e.g. staff, students, passersby	Likelihood	Severity	Risk rating					
						0					
						0					
						0					
						0					
						0					
						0					
						0					
						0					
						0					

Risk Matrix

Risk rating is calculated by multiplying value of likelihood and severity/impact

A value should be assigned for the likelihood of an incident occurring based on the hazard from 1 to 5 and a value for the severity / impact of the hazard from 1 to 5. e.g. 3 x 2 = 6 (low hazard).

	5 CATASTROPHIC	5	10	15	20	25		
	4 MAJOR	4	8	12	16	20		
SEVERITY /	3 SERIOUS	3	6	9	12	15		
IMPACT	2 MODERATE	2	4	6	8	10		
	1 MINOR	1	2	3	4	5		
		1	2	3	4	5		
		RARE	UNLIKELY	POSSIBLE	LIKELY	ALMOST CERTAIN		
		LIKELIHOOD						

Risk score = like	elihood of the hazard to caus	e harm ximpact
High	Medium	Low
Rating 15 or more	Rating 8 - 12	Rating 1 – 6
Immediate action is required to control and/or lower the level of risk. Exposure to the identified hazard is prohibited or severely restricted	Urgent review of the equipment, activities, system of work within the workplace with the aim of lowering the risk to the next level.	Usually, no further action will be required except for monitoring to ensure the risk does not change. However, if it is possible to reduce the risk levels still further, by using controls that are "reasonably practicable", then this should be done.

Postgraduate Ethics Application Form

COMMENT							
	_	м.	_	v.,	₩.	-1	_
			_				

	O	FFICE USE ONLY						
Date submitted: Ref:								
Reviewers:		Decision:						
Research Ethics Committee-Faculty of Pharmacy								
Res								
Note for the applican		p <mark>lication Form</mark>						
Note for the applicant The MSA Faculty of Pl		thics Committee (RF)						
ensuring that any rese	earch undertaken by f	aculty members or st						
institutions when in co standards. Where ethi								
commence until appro								
The Application Form	n consists of 3 secti	ons and 4 Annexes: Used Sections &						
TABLE OF CONTENTS	MANDATORY / OPTIONAL	Annex are marked						
	OPTIONAL	with √						
SECTION A: General Information, study								
description, research procedures General	MANDATORY							
information, study description, research	WANDATORT							
procedures and Supervisor Declaration								
SECTION B:								
Researches involving human participants	Optional							
SECTION C:	Ontional							
Researches involving animal use	Optional							
Annex I Risk Assessment form								
Annex II Participant Information sheet and Patient Consent Form	Optional							
Annex III Information Sheet on drug or medicinal products used in animal research	Optional							
This Application F Section A is Manda - For any inquiries, please - The form should be word - Return one hard copy of the	consult Dr.Reham Wasfi (processed.	nd C are optional. (Room G009) or send an						
		Section A						
Title of the Research	Study:							
Grade of protocol:								
Part I: Applicant ar	nd Supervisor Deta	nils						
1. Name of Applicant affilation	t (from MSA) and							
ID of MSA students (if applicable)							
2. Collaborating rese affiliated)	archers (non MSA							

3. E-mail Address
4.Telephone Number

_	_	-	_	•	_
CO	M	М	_	NΙ	4.
	W	M		M	

	OF	FICE USE ONLY			
Date submitted:		Ref:			
Reviewers:		Decision:			
_			ılty of Pharmacy		
Res					
	•	pplication Form	l		
5. Responsibilities of investigator:					
6. Name of sponsors/ organization and add					
7. Name and address institutes:	of collaborating				
Section II:Summary					
8.What is the type of	proposed research	?			
9. Brief background o	on the research topi	c and rational for ma	aking this research. \	Write references	
of literature cited. Li	mit = 300 words.				
References:					
rtororonoco.					
10. List the study aim	ns , objectives and b	enefits of this propo	sed research Limit :	= 100 words.	
11. Brief outline of the graphic outline of the	e proposed researc e study design (opti	h (include research onal) Limit = 300 wo	design and methodo ords.	ology). Add a	
12. What do you cons			h may arise with the	proposed study	
and what steps will b	be taken to address	tnese issues?			

	OFFICE USE ONLY									
Date submitted:		Ref:								
Reviewers:		Decision:								
Res	Research Ethics Committee-Faculty of Pharmacy Application Form									
13. What is the antici	pated date to finish	this research?								
14. Is this study spor What is the estimate		a specific organizat	ion other than MSA L	Iniversity?						
15. Have any collaborating internal or external schools or institutions or departments whose resources will be needed, been informed and agreed to participate?										
16. Brief outline of the work carried by collaborating institutions or departments. What do you consider to be the main ethical issues in that work? (Describe the steps taken to address these ethical issues in the specified part of the ethics application form)										
Applicant's Signature		Date								
Head of the Research Ethics Committee		Date								
	Appl	licant Declarati	on							
For the Research und	der the title:									
Carried by:										
I declare that I am aw ethics form.	I declare that I am aware of my obligation to respect all the matters mentioned in the introduced									
written form and acq - Respect the confide performance of this - Make sure that any rules and all experim	In particular, I will - Not change any step of the research plan, except after informing the ethics committee via a written form and acquire their permit. - Respect the confidentiality / restriction of any information brought to my attention during the performance of this research work. - Make sure that any experiment done in a facility outside MSA will follow all ethical and safety rules and all experiments carried by this facility will be mentioned in the ethics form. - Not make any information available to the public, even after completion of my assignment.									
Supervisor Signature	:			Date						
upervisor Signature: Date										

	M	M	
CO			

	OF	FICE USE ONLY			
Date submitted:		Ref:			
Reviewers:		Decision:			
Research Ethics Committee-Faculty of Pharmacy Application Form					
Please describe:					
1. How many particip involved?					
2. What are the main exclusion criteria for participants?	involved				
3. Will any participan research study be si involved in any other	multaneously				
4. Will human particip compensation for pa					
b. HUMAN PARTICIPA		CONSENT			
This part for the case					
1. Will informed cons If no, please justify	Ĺ				
2. How will informed obtained and by who					
3. Will participants be informed of their right to refuse to participate and their right to withdraw from this research study? Please elaborate.					
4. Will there be a time giving information au consent?					
5. Will any research p under the age of 18?					
c. Data Protection and	d Confidentiality				
Researchers must			Protection Act and the University		
1. Will the research ir potential research pa	volve any of the foll		y any stage (including identification of		
		cal records by those o	outside the research facility, or within		
			nedia, e-mail or computer networks		
	Sharing of data with o	<u> </u>	·		
	Export of data outside	e the country			
			es, e-mails or telephone numbers		
	Publication of direct q	•			
	Publication of data that	•	cation of individuals		
	Use of audio/visual re		audin au		
	Storage of personal d	iata on any of the follo	owing: Manual files		
			MSA computers		
			Home or other personal computers		
			Laptop computers		
2.What measures have been put in place to ensure confidentiality of personal data? Give details of whether any encryption or other anonymisation procedures have been used and at what stage?					
		n the study take nla			

undertaken?

	OF	FICE USE ONLY			
Date submitted:		Ref:			
Reviewers:		Decision:			
Research Ethics Committee-Faculty of Pharmacy					
	Ap	plication Form	1		
4 Who will have son	tual of and act ac the		lata generated by the	atudu?	
4. Willo will have con	troi or and act as the	custodian for the d	ata generated by the	study f	
			1		
Applicant's Signature		Date			
Supervisor's		Date			
Signature Head of the					
Research Ethics Committee		Date			
		Section C			
This want is fauth a st	unding that involves t	•			
This part is for the st					
a. What is the pur	·				
1.Field study/capture		ng (including feral)	animals		
2.Behaviour observa		-			
3.Harvesting of tissu		IS			
4.Dissection of dead 5.Surgical procedure					
6. Administration of		nte			
7.Infection with micro			tovine [i]		
8.Production of antis		Jarasites/ testing or	toxiiis [i]		
9.Feeding studies, in		ation			
10.Animals with alter			fied, naturally		
occurring mutation)					
11. Other Procedures	s: if selected, please	write details in the	box below		
A missoul 11					
Animal Housing					
a) Housing			::	all bains	
			icant impact on animal roints to consider are t	•	
maximum/minimum aı	nimals per cage/pen, i	isolation, group housi	ing (stocking rates, sex	es), shelter,	
bedding, hiding areas, environmental enrichment, conditioning period, day to day husbandry of the					
animal/s, eg diet, and how the normal environment of native animals is approximated.					
b) Site where proced	ures are to be carrie	d out			

_	-		_	•	_
CO	M	M	ı	NI.	
	W	111	Н		

	OF	FICE USE ONLY			
Date submitted:		Ref:			
Reviewers:		Decision:			
Res		committee-Facu pplication Form	ulty of Pharmacy		
c) Holding time					
What is the maximum	time for which any ind	dividual animal will be	held?		
d) Monitoring by Inve	estigators				
the method and freque problem is identified?	Write in details how the wellbeing of animals will be assessed throughout the project including: Details of the method and frequency of monitoring animals during and after procedures. What will be done if a problem is identified? Please include the criteria used for intervention, treatment, or withdrawal of the animals from the project. Who will be responsible for the management of veterinary and other				
a) Fata of Animala					
e) Fate of Animals	· · · · la at the commisti		10 If a viscale and to be quithonized		
How will this be done			nt? If animals are to be euthanized,		
f) Risks					
Please specify any special risks to other animals or humans arising from the project					
Applicant's Signature		Date			
Supervisor's		Date			

Applicant's Signature	Date
Supervisor's Signature	Date
*Signature of the Head of pharmacology department in MSA	Date
Head of the Research Ethics Committee	Date

*This signature is required only If this part of practical work will be done in the Animal House of MSA

SIGN HER	E TOAPPROVE THE		OFFICE USE ONLY		СОММ
	FILLED CONTENT IN				TS
	ANNEX la	Date		Ref:	
	AUTEXIA	submitted:			
Researche		Reviewers		Decision:	
signature:		:		Decision:	
signature: Revie		_			
ver					
wei signat					
ıre:					
are.					
			Amayla		
			Annex la		
			Risk Assessment		
			<u>Form</u>		
	Hazards inherent in the		Precautions (control		
Equiment	task or process Include	_	measures) include precautions		
/ Tool /	all the significant	Person (s)	for all individuals /groups that	Remar	
Biological	hazards that are	at risk	may be affected by the hazards	ks	
agent /	expected or are		you have identified e.g. staff,		
Waste	foreseeable in the		students, passersby		
	context of the work or process that is being				
	undertaken and where				
	it will be done				
uinmont	s and tools				
ersonal sa a: physica		isabilitv or	health problem, getting los	st or stranded by transport,	
	legal differences	•	, , , ,	, ,	
ological c	agent hazards				
ological a	agent nazarus				
		I			
	ental impact				
.g.: pollu	ition and waste, depo	sition of ru	ıbbish		
Other haz	ards				

	OVE THE FILLED CONTENT IN		OFFICE USE ONLY		COMMENTS
	ANNEX Ib	Date		Ref:	
		submitted			
		:			
Researcher		Reviewers		Decision	
signature:		:		:	
Reviewer					
signature:			A 10:		
			Annex Ib isk Assessment Form		
			al hazards e.g.: Toxic by		
		inhala	tion, irritant , corrosive,		
		flammable	e, explosive Include routes		
		of expo	sure: skin sensitization,		
		sensiti	zation by inhalation "		
2	Hazards inherent in		Precautions (control		
3 Chemical	the chemical	D (-)		D	
5 Compoun	Including all the	Person(s) at risk	measures) include	Remarks	
6 ds	significant hazards	atrisk	precautions for all		
7	that are expected or		individuals /groups that		
9	are foreseeable in		may be affected by the		
10	the context of the		hazards you have		
Chemical Compoun ds 8 9 10 11 12 13 14 15	work or process that		identified e.g. staff,		
13	is being undertaken		students, passersby		
14	and where it will be				
15 16	done				
17					
18 19					
20					
21					
22 23					
24					
25 26					
27 					
28					
29 30					
31					
32 33					
34					
35 36					
37					
38					
39 40					
41					
42 43					
44					
45 46 47 48 49 59					
47					
48					
19					
51					1

CO	ΜN	ΠEΝ	ΠS

اسماء الباحثين:

	0	FFICE USE ONLY	1		
Date submitted:		Ref:			
Reviewers:		Decision:			
		Annex IIa cal trial or clinica icipant Informa			
Invitation: You are	invited to participate				
Conducted by (plea	ase include the name	s of the students a	nd their ID numbers):		
Supervised by (plea	ase include the supe	rvisor name and aff	filiation):		
University. Before you are fully aware would your participyou sign the particiare free to withdraw	This research has been approved by the ethics committee of the Faculty of Pharmacy-MSA University. Before you decide whether or not to participate in this study, please make sure that you are fully aware with the details of the study and what exactly is required from you and how would your participation affect the study. Please take the time to read the following parts before you sign the participant consent form. Your participation in this research is voluntarily and you are free to withdraw at any time, without providing reasons.				
What is the purpos	What is the purpose of this research? Write a brief outline on this study.				
What is required fro	om the participant? A	And why is he/she b	peen invited?		
What are the risks a	associated with the p	proposed procedure	e(s)?		
What is the expecte	ed time for finishing	the research?			
I declare that I have	ve read all the infor	rmation in the part	ticipant information sheet and		
agree to participa	te in this research				
Participant signatu	re:				
If you find any prob	olem in this research	you can contact th	e following researcher		
Name:		70	5 (C5		
Contact information	n:				
		sponsible for pres	serving the confidentiality of		
	d participant's pers				
Researcher (studer	nts) signature:				
	÷ 1	<u>ملحق </u>	44		
	ي البحث	معلومات للمشاركين في	ور <u>هه م</u> رسالة دعوة: أنت مدعو للمشاركة في دراسة بحث		
		بيد بحوان:	رسال دحوه: الله مدحو للمسارحة في دراسة بح		

				COMMENTS		
	0	FFICE USE ONLY	1			
Date submitted:		Ref:				
Reviewers:		Decision:				
		Annex IIa				
	(used in Clini	cal trial or clinic	al racearch)			
	Part 1: Part	icipant Informa	ition Sneet			
كنت ترغب في المشاركة	يدلة. قبل أن تقرر ما إذا ا	خلاقيات التابعة لكلية الص	هذا البحث تم الموافقة عليه من قبل لجنة الأم			
يرجى أخذ الوقت الكافي	ت وما سينطوي عليه	م لماذا يتم اجراء هذا البد	في هذه الدراسة، فمن المهم بالنسبة لك أن نفه			
ت حرفي الانسحاب في	، هذا البحث هو طوعي وأن	المشاركين. مشاركتكم في	لقراءة ما يلي قبل التوقيع على استمارة موافقة			
			أي وقت، دون إبداء أسباب			
		البحث.	ماهى اهداف هذا البحث؟ اكتب باختصار خطوات			
		عوتكم للمشاركة؟	ما هو الدور المطلوب من المشارك؟ و لماذا تم د			
		3 1 3	1 3 3 2 .3 33 3			
			ما هي المخاطر المرتبطة بهذا الإجراء؟			
			الوقت المتوقع لانتهاء البحث			
			, , ,			
5 11 /*	Talk to the action of the		that the aiss of si			
في هذا البحث	تبارك وافقت على المشاركة	ردة في ورقة المعلومات م	أقر بأنني قد قرأت جميع المعلومات الوا			
			توقيع المشارك:			
	، الاتصال بالباحث	مكلة في هذا البحث يمكنك	إذا وجدت أي مش			
			الأسم:			
			·			
			معلومات الإتصال:			
شاركين.	عة و البيانات الشخصية للمن	على سرية المعلومات المجه	يقر الباحث بمسؤليته على الحفاظ			
			توقيع الباحث:			
			1 7 7 7			

	(OFFICE USE ONL	_Y		
Date submitted:		Ref:			
Reviewers:		Decision:			
		Annex IIb			
	Dart 2. Informatic		Medicinal product		
		on on drugs or h	ACHOICHIIBIE OTOTOTOM	S	
	This annex needs only to be completed if relevant to research. It should be completed when Drug or medicinal products or medical devices are used on Human participants.				
Title of Research:					
1 le the study initia	ated /sponsored by p	harmacoutical or of	har industrial		
company?	ateu /sponsoreu by p	marmaceutical or of	iller illuustriai		
2. Does the study i	nvolve:				
	- Pre-marketing use of	of a product?			
	- A new use for mark	eted product?			
	- Studying the effect	of marketed product?			
1) Drug and Medici	•				
			bstances presented as	having properties	
	nting disease in humar or combination of subst		used in or administered	d to human beings	
			ical functions by exertir		
pharmacological, im	munological or metabo	olic action, or to making	ng a medical diagnosis.		
a) Details of the me	adicinal product:				
Approved Name	Active ingredient	Strength	Manufacturer		
Approved Name	Active ingredient	Strength	Manufacturer		
b) Dosage regimen	Lucadi				
, ,	Frequency	D,	oute		
Dosage &	litequency	K	Jule		
c) le this dosage re	aimen				
c) Is this dosage re	I dose regimen by the	manufacture			
- New dose regimen		manadadare			
_	ssible side effects?				
,					
e) What is the phar	macological action of	of this drug?			
	<u> </u>				
f) What are the arra	angements for disper	nsing medicinal pro	duct? (please give de	tails)	
,	у тэ. ш.эрог	J	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
2) Medical devices					
	Is the focus of this study/trial to investigate/evaluate a medical device?				
	name of the medical	device or device nom	enclature (system of na	aming the medical	
device)?If ves. please pro	vide a general descrip	tion of the medical de	evice and the medical u	se in patients.	
 If yes, please provide a general description of the medical device and the medical use in patients. If an application to conduct a clinical investigation of a medical device 					
(a) Does the device	e have a CE mark?				
	a CE mark, is it propo				
device within the to terms of its CE mai	erms of its CE mark ork?	or outside the			
If outside, please					
Jaioido, picase					

• CE mark* number:

OFFICE USE ONLY			
Date submitted:		Ref:	
Reviewers:		Decision:	
			_

COMMENTS

• Who will fit or apply the device for participant?

NOTE: CE Marking on a product is a manufacturer's declaration that the product complies with the essential requirements of the relevant European health, safety and environmental protection legislation, in practice by many of the so-called Product Directives.

Research Ethics Committee-Faculty of Pharmacy

Annex IIc

Part 3: Patient Consent Form

Title of Research:

Signature of Researcher/person taking the consent

- I confirm that I have read and understand the Information Sheet for the above study, have had the opportunity to ask questions, and understand what I am expected to do as a volunteer. - I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my rights being affected.
- I would like/not like my own results reported back to me, understanding that no interpretation may be possible. (answer yes/No)

illustration purpos every effort will be agree) - I do/do not agree	es in reports and and made to preserve that samples provunderstand that the	ny subsequent journal articles. my anonymity, this cannot be vided during the study may be	during the study may be used for This is on the understanding that, while guaranteed. (answer agree/not stored beyond the study duration for nymous and not traceable back to me.
Participant signatur	e:		وقيع المشارك:
		Certificate of Consent for chi	ildren
and any questions of participate as a participate	that I have asked have ticipant in this study	ve been answered to my satisfac	ad the opportunity to ask questions about it tion. I consent voluntarily for (child) to right to withdraw her/him from the study at
Print Name of			
Parent or Guardian		Data	
Signature of Parent of Guardian		Date	
		Certificate of Consent for illi	torato
	e accurate reading o		al participant, and the individual has had the
			,
Print name of witness		Date	
Signature of witness			
Thumb print of participant		Date	
	Statemer	nt by the researcher/person t	aking consent
	ead out the informati		ant, and to the best of my ability made sure
		3	
by the participant h	ave been answered		about the study, and all the questions asked bility. I confirm that the individual has not y and voluntarily.
		en provided to the participant.	
Drint Name of			
Print Name of Researcher/person			
taking the consent		Dete	

Date

CO	M	M	Э	M	ΓG

D		OFFICE USE ONI	_Y	
Date submitted:		Ref:		
Reviewers:		Decision:		
		Annex III		
Information	on on druas or N	Medicinal produc	cts used in anima	l research
			esearch. It should be are used on human e	
Title of Research:				
company?	ated /sponsored by p	pharmaceutical or of	ther industrial	
2. Does the study i				
	- Pre-marketing use of	•		
	 A new use for mark Studying the effect 	eted product? of marketed product?	,	
	- Studying the effect	or marketed product?		
for treating or prever (b) Any substance o either with a view to	is: (a) Any substance nting disease in human r combination of subst restoring, correcting of	n beings; or tances which may be or modifying physiolog	bstances presented as used in or administered pical functions by exerting a medical diagnosis.	d to human beings
a) Details of the me	edicinal product:			
Approved Name	Active ingredient	Strength	Manufacturer	
b) Dosage regimen	used:			
Dosage &	Frequency	Re	oute	
c) Is this dosage re	aimon			
,	I dose regimen by the	manufacture		
- New dose regimen				
d) What are the pos	ssible side effects?			
e) What is the phar	macological action of	of this drug?		
f) What are the arra	angements for dispe	nsing medicinal pro	duct? (please give de	tails)
2) Medical devices				
•	s study/trial to investig	ate/evaluate a medic	al device?	
			nenclature (system of na	aming the medical
If an application to	o conduct a clinical inv		evice and the medical u cal device	se in patients.
(a) Does the device				
	a CE mark, is it properms of its CE mark of			
If outside, please				
ii outside, piease	ciaborate.			

• CE mark* number:

	OFFICE USE ONL	Υ_
Date submitted:	Ref:	
Reviewers:	Decision:	
		_

COMMENTS

• Who will fit or apply the device for participant?

NOTE: CE Marking on a product is a manufacturer's declaration that the product complies with the essential requirements of the relevant European health, safety and environmental protection legislation, in practice by many of the so-called Product Directives.

MSA University	MSA University	MSA University	MSA University	MSA University
	(OFFICE USE ONI	_Y	
Date submitted:		Ref:		
Reviewers:		Decision:		
	Research	Protocol	Approval	University October University for Modern Sciences and Arts بانة أكثوير للغوم الحنية والأناب
Title of Research:				
Carried by: (Applicant's name a	and affiliation)			
			of pharmacy has r mmittee and has o	
Decision:				
The DeclarationThe National StaThe National OcNational Code of	of Helsinki tement on Ethical cupational Health a	Conduct on Huma and Safety Commi reparation of Mate	ssion guidelines; rial Safety Data Shee	
Head of the Research Ethics Committee		dd/mm/yyyy		
MSA University	MSA University	MSA University	MSA University	MSA University

Postgraduate Progress Report

MSA
IN EGYPT SINCE 1996 Established by Dt.Nawal El Degwi IM S A U N I V E R S I T N جامعة أكتوبر للعلهم الحديثة والأداب

OFFICE USE ONLY	IN ECYPT S Established by D
Date submitted:	MSA UNI وم الحديثة والأداب Ref:
Submission number:	
Reviewers:	
Decision:	

Research Ethics Committee-Faculty of Pharmacy

Progress Report

Research title	
Applicant (s) and affiliation	
(s)	
Department	

This form should be filled by applicants to state the modifications in their running research. This form must be delivered to the ethics committee: (1) once a year, (2) in case of any modifications (if any) in the information submitted in the original ethics application form in part one and (3) any serious unexpected adverse events.

Is there any modifications in protocol of work	Yes/No
Other modifications in the research	Yes/No
Are there any documents that you are going to attach to this form	Yes/No

Annlican	t signature			

		nics committee
	Is this modifica	ation considered major
		Minor
Th	e ethics committee com	ment and recommendations on thesemodifications
This	s part is filled by the Ethics c	committee after fulfilling the recommendations of the Ethics
		committee after fulfilling the recommendations of the Ethics
c <mark>o</mark> mmi		committee after fulfilling the recommendations of the Ethics or not approved
ommi	ittee is research is approved	
c <mark>o</mark> mmi	is research is approved Reviewer's signature	
c <mark>o</mark> mmi	Reviewer's signature Head of the ethics	
c <mark>o</mark> mmi	is research is approved Reviewer's signature	